Atlanta, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has debuted a new quality module for eValuator and successfully implemented that module at an existing eValuator client.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. eValuator’s AI-enhanced pre-bill code auditing ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide while avoiding denials. The eValuator quality module enables health systems to prospectively assess the risk score of individual claims and their estimated impact on overall quality measurement in real time. By eliminating manual, post-hoc risk scoring practices, the quality module introduces an industry-leading workflow that allows for correction of coding errors signaled by risk scores.
“We developed the quality module based on market research and were fortunate to build it in collaboration with existing eValuator clients to provide maximum value for health systems nationwide.” stated Ben Stilwill, President and Chief Executive Officer, Streamline. “We expect the insights this quality module delivers will improve the quality of care our clients are able to provide while bolstering our ability to ensure health systems are accurately paid for the care they’ve provided.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
Last Trade: | US$5.33 |
Daily Volume: | 0 |
Market Cap: | US$23.250M |
May 01, 2025 January 22, 2025 December 18, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load